In sum, the improved viral production observed in CD4+ T-cells after treatment with supernatants derived from 25 ng/ml MIF-treated infected MDMs could not to be explained by differential cell viability, infection percentage, or cell activation (measured by surface markers). The gene discussed is MIF; the disease is infection.